Selpercatinib in Thyroid Cancer (Collaboration with the International Thyroid Oncology Group)
Contact
Description
This study involves taking a study drug called selpercatinib. The overall goal of this study is to find out how effective the study drug is in combination with radioactive iodine (I-131) in treating people with thyroid cancer. The study drug will be given in combination with treatments you will receive as part of your regular cancer care (I-131 and thyrotropin alfa).
Eligibility and criteria
IRB Number:
23-021515
Eligible age range:
Clinical trial phase:
Phase II
Official title:
Related specialties
Related conditions
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.